永太科技(002326) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 90.82% to CNY 16,126,057.89 for the reporting period[9] - Operating revenue for the period was CNY 888,026,581.27, down 10.07% year-on-year[9] - Basic earnings per share dropped by 89.84% to CNY 0.019[9] - The company reported a net profit of ¥1,456,982,384.53, up from ¥1,229,788,973.69, representing an increase of about 18.5%[59] - Net profit for the current period was ¥15,656,624.15, down 90.0% from ¥173,603,011.83 in the previous period[73] - The net profit for the current period is $53.87 million, down 65.6% from $156.47 million in the previous period[77] - The net profit for the current period is ¥247,142,692.47, down 5.4% from ¥261,248,442.25 in the previous period[92] Revenue and Costs - Total operating revenue for the current period was ¥888,026,581.27, a decrease of 10.1% from ¥987,442,262.52 in the previous period[69] - Total operating costs increased to ¥877,182,302.32 from ¥834,058,947.26, representing a rise of 5.2%[69] - The company's operating revenue for the current period is $339.32 million, a decrease of 23.6% compared to $444.36 million in the previous period[77] - Operating costs decreased to $227.31 million from $256.95 million, reflecting a reduction of 11.5%[77] Cash Flow - The net cash flow from operating activities increased by 109.12% to CNY 241,979,383.36[9] - The company's cash and cash equivalents as of September 30, 2020, amount to 570.50 million CNY, compared to 705.63 million CNY at the end of the previous period[50] - The net cash flow from operating activities was -97,100,707.77 CNY, slightly improved from -97,642,848.93 CNY in the previous period[104] - Cash inflow from investment activities totaled 197,278,718.39 CNY, compared to 96,630,416.11 CNY in the prior period[104] - The total cash inflow from operating activities is ¥2,583,071,272.86, compared to ¥2,491,779,814.24 in the previous period[96] Shareholder Information - The total number of shareholders at the end of the reporting period was 88,238[14] - The largest shareholder, Wang Yingmei, holds 17.78% of the shares, totaling 155,850,400 shares[14] Assets and Liabilities - Total assets increased by 6.11% to CNY 7,286,156,272.52 compared to the end of the previous year[9] - Total liabilities rose to ¥3,706,403,302.03, compared to ¥3,505,153,752.04, indicating an increase of around 5.7%[56] - Owner's equity increased to ¥3,579,752,970.49 from ¥3,361,216,103.42, marking a growth of approximately 6.5%[59] - Total liabilities reached ¥3,505,153,752.04, with current liabilities at ¥3,004,177,475.64 and non-current liabilities at ¥500,976,276.40[116] Research and Development - Research and development expenses rose by 52.86% year-on-year, reflecting increased investment in R&D activities[28] - Research and development expenses for the current period were ¥33,772,234.82, up 53.3% from ¥22,093,270.69[69] - Research and development expenses increased to ¥44,976,958.33, up 18.5% from ¥38,014,618.63 in the previous period[89] Investment Income - Investment income surged by 295.39% year-on-year, mainly due to the sale of part of the Fuxiang Pharmaceutical stocks[30] - The company’s investment income for the current period is $21.60 million, a significant recovery from a loss of $0.88 million in the previous period[77] - The company reported a significant increase in investment income, reaching ¥70,400,429.36 compared to ¥9,979,615.02 in the previous period[89] Financial Expenses - The weighted average return on net assets decreased to 0.48%, down 5.01% from the previous year[9] - The company reported a 221.24% year-on-year increase in financial expenses, largely due to exchange losses from currency fluctuations[28] - Financial expenses increased significantly to ¥43,306,278.79 from ¥13,480,783.42, marking a rise of 221.5%[69] - The company’s financial expenses increased to $22.89 million, compared to $15.30 million in the previous period, reflecting a rise of 49.5%[77] Other Comprehensive Income - Other comprehensive income after tax was -¥2,260,077.15, compared to ¥1,901,258.17 in the previous period[73] - The total comprehensive income for the current period was ¥13,396,547.00, down 92.4% from ¥175,504,270.00[73] - The total comprehensive income for the current period is $53.87 million, down 65.6% from $156.47 million in the previous period[80] Risk Management - The company has established strict risk control systems for derivative investments, including authorization, approval, and regular risk factor analysis[40]